Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Arctic Bioscience AS ( (DE:9TD) ).
Arctic Bioscience has registered an increase in its share capital with the Norwegian Register of Business Enterprises following the exercise of debt conversion rights, raising its share capital from NOK 2,668,934 to NOK 2,685,934. This development reflects the company’s ongoing efforts to strengthen its financial position and potentially enhance its market presence, which could have implications for stakeholders as the company continues to advance its pharmaceutical and nutraceutical initiatives.
More about Arctic Bioscience AS
Arctic Bioscience is a biotech company that develops and commercializes pharmaceutical and nutraceutical products derived from unique bioactive marine compounds. The company is working on HRO350, a novel oral drug candidate aimed at treating mild-to-moderate psoriasis, addressing a significant need for effective and safe medications. Additionally, Arctic Bioscience’s nutraceuticals are marketed globally under the ROMEGA® brand as both bulk ingredients and finished goods.
YTD Price Performance: 42.15%
Average Trading Volume: 93,291
Current Market Cap: NOK69.39M
See more insights into 9TD stock on TipRanks’ Stock Analysis page.